Marinus Pharmaceuticals Inc (MRNS) Event June 01, 2022, 12:30 UTC (50% Neutral) Marinus Pharmaceuticals, Inc. (MRNS) Announces Regulatory Update Full text
Register to leave comments News bot Oct. 2, 2025, 3:01 a.m. 📋 Marinus Pharmaceuticals, Inc. (MRNS) - Regulatory Update Filing Date: 2022-06-01 Accepted: 2022-06-01 08:30:29 Event Type: Regulatory Update Event Details: Marinus Pharmaceuticals Inc (MRNS) Announces Regulatory Update Marinus Pharmaceuticals Inc (MRNS) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development: 🔬 Clinical Development Pipeline (Marinus Pharmaceuticals, Inc.): Product Type Development Stage Therapeutic Area Source Ganaxolone DRUG Phase PHASE3 Tuberous Sclerosis Complex ClinicalTrials.gov 💼 Business Developments: PartnershipAcquisition: Not availableLicensing: Not availableRegulatory ApprovalExecutive Changes: Not available Structured Data: Company Name: Marinus Pharmaceuticals IncCIK: 0001267813Ticker Symbol: MRNSPeriod End Date: 2022-05-19Document Type: 8-K
📋 Marinus Pharmaceuticals, Inc. (MRNS) - Regulatory Update
Filing Date: 2022-06-01
Accepted: 2022-06-01 08:30:29
Event Type: Regulatory Update
Event Details:
🔬 Clinical Development Pipeline (Marinus Pharmaceuticals, Inc.):
💼 Business Developments:
Structured Data: